Hematology

Among the 31 patients evaluable for efficacy analysis, ORR was 100%.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.

Review top news and interview highlights from the week ending September 9, 2022.

The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.

SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.

Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has requested additional preclinical data from Beam Therapeutics on BEAM-201.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.

Review top news and interview highlights from the week ending September 2, 2022.

The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A pre-treatment TME with high levels of cytokines and chemokines was associated with complete response to axi-cel treatment.

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed the collaboration and research that went into developing beti-cel.

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

Review top news and interview highlights from the week ending August 26, 2022.

The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.

Century Therapeutics will initiate the phase 1 ELiPSE-1 study imminently.

The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.

BioMarin plans to resubmit the biologics license application for val-rox to the FDA by the end of September 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed requirements for administering beti-cel.

At a median follow-up of 24 months, the best ORR achieved was 77.6% among 58 evaluable patients with large B-cell lymphoma treated with relma-cel.